Cu 67
61.8 h
β- 0.4, 0.6...
γ 1852, 93, 91...

Chemical properties

In solution Cu-67 is usually in divalent state. It can be radiolabelled with macrocyclic chelators. DOTA is being used, but other, specific copper chelators such as MeCOSar may provide improved stability.

Nuclear properties

Cu-67 decays by β- decay with a half-life of 2.576(5) days to stable Zn-67. It emits a low energy β- spectrum with 145 keV average energy and 561 keV maximum energy based on branching ratios measured by Chen et al. . In addition to β- emission it also emits low energy conversion and Auger electrons , thus emitting in total about 1.2 electrons (with energies above 7 keV) per decay.

Moreover, Cu-67 emits γ-rays at 184.6 keV (44.2%) and 91.3 / 93.3 keV (together 21.1%)  which are suitable for SPECT imaging.

The mean electron energy emitted per decay is 148 keV, the mean photon energy per decay is 101 keV .


Cu-67 is produced by proton irradiation of enriched Zn-70 targets at Hevesy Lab, DTU, Denmark.

Cu-67 is produced by deuteron irradiation of enriched Zn-70 targets at the cyclotron ARRONAX, Nantes, France.


The radiochemical separation is performed at production site and activity will be shipped from there to the users in form of CuCl2 solution.

Examples of use

  • Cu-67 forms a theranostic pair together with Cu-64.
  • Medium energy collimators are recommended for SPECT imaging with Cu-67 .
  • Clinical trials with Cu-67-radioimmunotherapy have been performed in the past.
  • Clinical trials with Cu-67-peptide receptor radionuclide therapy and Cu-67-PSMA radioligand therapy are ongoing.

Purity grades available


No carrier added (n.c.a.)

Production routeZn-70(p,α)Cu-67 or Zn-70(d,αn)Cu-67
DaughterDecays to stable Zn-67: 100% β-
Half-life61.8 h
Processing2-step column separation
Primary Container2.5 mL borosilicate glass V-vial with silicone rubber screw cap
Product Graden.c.a.
Physical FormLiquid or solid deposit
Chemical FormIn 0.1 M HCl (evaporation to dryness is also possible)
Radioactive Concentration (gamma spectrometry)n.a.
AppearanceClear colourless solution
Radionuclide identification (gamma spectrometry)185 keV gamma line present
Radionuclidic Purity (gamma spectrometry)Not yet defined
Chemical purity (ICP-OES)n.a.
Molar activity (ICP-OES)n.a.
Apparent Molar Activityn.a.
Microbiological qualityn.a.
Bacterial endotoxinn.a.
pH (pH strips)Depends on chemical form
Additional information
Activity available200 MBq per batch (planning in advance)
Activity limit for UN2910 (excepted package) shipment0.7 GBq in dry state or 70 MBq in liquid form
Other information


  • β-therapy

Point of supply

  • Nantes, France
  • Risø, Denmark

Involved production facilities

DTU, Denmark

Involved biomedical facilities

To find out in which biomedical facilities you can use this radionuclide, contact the helpdesk.